Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato

Translated title of the contribution: Aromatase inhibitors in advanced breast cancer

Gian Paolo Spinelli, Federica Tomao, Evelina Miele, Giulia Pasciuti, Michelangelo Russillo, Silverio Tomao

Research output: Contribution to journalArticlepeer-review


Benefits from hormonal therapy in patients with hormon-sensitive breast cancers are widely and well known. A great challenge for clinicians is represented by the possibility to use citoreductive primary hormonal therapy in patients with locally advanced breast carcinoma. Five-year treatment with tamoxifen has been for long time the gold standard in adjuvant settings. In post-menopausal women affected by breast cancer larger than 3 cm and expressing estrogen receptors (ER+), clinical trials have shown that few months treatment with aromatase inhibitors can downsizing tumors. This citoreduction is greater than the one obtained with tamoxifen and it makes conservative surgery possible in most part of cases.

Translated title of the contributionAromatase inhibitors in advanced breast cancer
Original languageItalian
Pages (from-to)34-38
Number of pages5
JournalRecenti Progressi in Medicina
Issue number1
Publication statusPublished - Jan 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Aromatase inhibitors in advanced breast cancer'. Together they form a unique fingerprint.

Cite this